Business of regenerative medicine: scalability and sustainability — the facility of the future
Join our international panel for part one of their discussion.
In the first part of our expert panel on the business of regenerative medicine, learn more about the importance of considering scalability and sustainability when developing a cell therapy, its manufacture and eventual supply chain.
Plus, our panelists share their pain points and discuss how the facility of the future might address them.
Chaired by Michael May, CCRM, this panel discussion focuses on the key business challenges within regenerative medicine. Joining Michael were four leading voices in regenerative medicine and cell therapy, from research to manufacture: Robert Preti (Hitachi Chemical Advanced Therapeutics Solutions, LLC), Robert Jones (Fisher Bioservices), Carolyn Yeago (Georgia Institute of Technology) and Qasim Rafiq (UCL).